<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50181">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02452931</url>
  </required_header>
  <id_info>
    <org_study_id>TOL2581A</org_study_id>
    <nct_id>NCT02452931</nct_id>
    <nct_alias>NCT02811471</nct_alias>
  </id_info>
  <brief_title>Pharmacokinetic Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty</brief_title>
  <official_title>An Open-label, Single Arm, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Leuprolide Acetate 45 mg for Injectable Suspension Controlled Release in Subjects With Central (Gonadotropin-Dependent) Precocious Puberty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tolmar Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tolmar Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study determines the effectiveness of leuprolide acetate 45 mg for injectable
      suspension for treatment of children with Central Precocious Puberty.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Leuprolide acetate is a GnRH agonist that inhibits pituitary gonadotropin secretion by
      binding to the GnRH receptors and blocking downstream hormone synthesis. The steady decrease
      in hormone synthesis (LH and FSH) leads to a suppression of testicular and ovarian
      steroidogenesis. In children with CPP, this steady decrease in hormone synthesis disrupts
      the progression of puberty.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Suppression of Peak-Stimulated Luteinizing Hormone at 6 months.</measure>
    <time_frame>6 months</time_frame>
    <description>Luteinizing Hormone (LH) suppression is defined as peak-stimulated LH &lt; 4mIU/mL. Peak stimulated LH refers to the maximum LH concentration measured 30 minutes after a gonadotropin-releasing hormone agonst (GnRHa) stimulation test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with suppression of luteinizing hormone measured by blood levels.</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Precocious Puberty, Central</condition>
  <arm_group>
    <arm_group_label>Assigned Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Leuprolide acetate 45 mg will be administered as a subcutaneous injection at 6-month intervals for the 12 month study period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprolide Acetate 45 mg</intervention_name>
    <description>Subcutaneous injection</description>
    <arm_group_label>Assigned Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females age 2 to 8 years (inclusive) or males age 2 to 9 years (inclusive)

          -  Confirmed diagnosis of CPP within 12 months of Baseline Visit (Day 0) but have not
             received prior GnRH agonist treatment for CPP

          -  Pubertal-type LH response following an abbreviated GnRHa stimulation test before
             treatment initiation

          -  Clinical evidence of puberty, defined as Tanner stage ≥ 2 for breast development in
             females or testicular volume ≥ 4 mL in males

          -  Difference between bone age (Greulich and Pyle method) and chronological age ≥ 1 year

        Exclusion Criteria:

          -  Gonadotropin-independent (peripheral) precocious puberty

          -  Prior or current GnRH treatment for CPP

          -  Prior or current therapy with medroxyprogesterone acetate, growth hormone or
             insulin-like growth factor-1 (IGF-1)

          -  Diagnosis of short stature (ie, 2.25 standard deviations (SD) below the mean height
             for age)

          -  Known history of seizures, epilepsy, and/or central nervous system disorders that may
             be associated with seizures or convulsions

          -  Any other medical condition or serious intercurrent illness that, in the opinion of
             the Investigator, may make it undesirable for the subject to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>9 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peggy Schorr</last_name>
    <role>Study Director</role>
    <affiliation>orphan reach USA, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peggy Schorr</last_name>
    <phone>856-229-0505</phone>
    <email>pschorr@orphan-reach.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pediatric Endocrinology of Phoenix</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85053</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fran Hoekstra, RN</last_name>
      <phone>623-748-4700</phone>
      <email>fran@pedendophoenix.com</email>
    </contact>
    <investigator>
      <last_name>Tala Dajani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marla Hashiguchi</last_name>
      <phone>858-966-8940</phone>
      <email>mhashiguchi@rchsd.org</email>
    </contact>
    <investigator>
      <last_name>Karen Klein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Joe DiMaggio Children's Hospital</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paulette Smith</last_name>
      <phone>954-265-6388</phone>
      <email>PSmith@mhs.net</email>
    </contact>
    <investigator>
      <last_name>Martha Taboada, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keisha Bird</last_name>
      <phone>904-697-3122</phone>
      <email>kbird@nemours.org</email>
    </contact>
    <investigator>
      <last_name>Nelly Mauras, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Wilson, RN</last_name>
      <phone>407-567-6201</phone>
      <email>jennifer.wilson@nemours.org</email>
    </contact>
    <investigator>
      <last_name>Matthew Benson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children at Indiana University Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Didrick, RN</last_name>
      <phone>317-944-3889</phone>
      <email>pdidrick@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Erica Eugster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pediatric Endocrine Associates</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Halverson</last_name>
      <phone>612-625-0673</phone>
      <email>halve423@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Bradley Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center, Endocrine</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Schultz</last_name>
      <phone>513-636-4744</phone>
      <email>carrie.schultz@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Susan Rose, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma College of Medicine</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharnella Goudeau</last_name>
      <phone>918-619-4304</phone>
      <email>Sharnella-goudeau@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>David H Jelley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Kearns, RN</last_name>
      <phone>206-987-2000</phone>
      <email>sue.kearns@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Sara DiVall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MultiCare Institute for Research and Innovation</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Garrison</last_name>
      <phone>253-301-6990</phone>
      <email>kathryn.garrison@multicare.org</email>
    </contact>
    <investigator>
      <last_name>Gad Kletter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Ninos</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1425EFD</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Analia Freire, MD</last_name>
      <phone>541149617705</phone>
      <email>freireav@yahoo.com.ar</email>
    </contact>
    <investigator>
      <last_name>Mirta Graciela Gryngarten, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Calgary, Alberta Children's Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Gougeon</last_name>
      <phone>403-955-2910</phone>
      <email>Claire.Gougeon@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Daniele Pacaud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitair Ste-Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Champagne</last_name>
      <phone>15143454798</phone>
      <email>caroline.champagne@recherche-ste-justine.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Cheri Deal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Pepin</last_name>
      <phone>5149341934</phone>
      <phone_ext>23737</phone_ext>
      <email>sandra.pepin@muhc.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>John Mitchell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Quebec-Universite Laval</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louise Gosselin</last_name>
      <phone>418-525-4444</phone>
      <phone_ext>48290</phone_ext>
      <email>louise.gosselin@mail.chuq.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Dardye Eugene, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigaciones Materno Infantil (IDIMI)</name>
      <address>
        <city>Santiago</city>
        <state>Metropolitana</state>
        <zip>8360160</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alejandra Avila, RN</last_name>
      <phone>56229770850</phone>
      <email>aleavila@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ximena Gaete Vasquez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Regional de Antofagasta Leonardo Guzman</name>
      <address>
        <city>Antofagasta</city>
        <state>Second Region</state>
        <zip>1270001</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasmina Letelier, RN</last_name>
      <phone>56967695194</phone>
      <email>yasmina.letelier@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jeannette Linares Moreno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Unversitario &quot;Dr. Jose Eleuterio Gonzalez&quot;</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigaciones Aplicadas a la Neurociencia, A.C.</name>
      <address>
        <city>Durango</city>
        <zip>34000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Lira Martinez, BSc</last_name>
      <phone>526188104148</phone>
      <email>v.h.lira.mtz@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Diana Gonzalez Fernandez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Liggins Institute, University of Auckland</name>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Biggs</last_name>
      <phone>64 9 923 6453</phone>
      <email>d.biggs@auckland.ac.nz</email>
    </contact>
    <investigator>
      <last_name>Paul Hofman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <zip>4710</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vesal Moeeni, MD</last_name>
      <phone>64 23 364 0747</phone>
      <phone_ext>80747</phone_ext>
      <email>vesal.moeeni@otago.ac.nz</email>
    </contact>
    <investigator>
      <last_name>Tony Walls, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wellington Hospital, Capital &amp; Coast Distric Health Board</name>
      <address>
        <city>Wellington</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Barrett</last_name>
      <phone>64 4 9185110</phone>
      <email>jonathan.barrett@ccdhb.org.nz</email>
    </contact>
    <investigator>
      <last_name>Esko Wiltshire, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 24, 2017</lastchanged_date>
  <firstreceived_date>May 5, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Puberty, Precocious</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
